Heidelberg Pharma's HDP-103 Shows Promise for Tough Prostate Cancer Cases

Heidelberg Pharma AG, a clinical-stage biotech company based in Ladenburg, Germany, is set to present groundbreaking preclinical data for its innovative cancer therapy HDP-103 at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2026 in San Diego. The company, listed on the Frankfurt Stock Exchange under the symbol HPHA, specializes in developing Antibody Drug Conjugates (ADCs) using its proprietary ATAC® technology platform, which leverages Amanitin—a potent compound derived from the green death cap mushroom. This unique approach represents a novel therapeutic modality in oncology, with HDP-103 specifically targeting metastatic castration-resistant prostate cancer (mCRPC), a challenging and aggressive form of the disease with high unmet medical needs. The presentation, detailed in a poster titled "HDP-103, a PSMA targeting amanitin-based ADC, is efficacious even in difficult to treat patient derived xenograft models with heterogenous PSMA expression," will showcase data from patient-derived xenograft models, highlighting the therapy's robust antitumor activity even in tumors with heterogeneous PSMA expression and those harboring a del(17p) genetic alteration.

The core findings reveal that HDP-103 demonstrates target-specific binding in human tissues and superior efficacy compared to an anti-PSMA Exatecan ADC in preclinical models. Key advantages include a comfortable therapeutic index, stable circulation without drug accumulation, dose-linearity, and a manageable safety profile with transient adverse effects primarily in the liver and kidney, which are known off-target effects of Amanitin-based ADCs and can be readily monitored. These results position HDP-103 as a promising candidate for further clinical development, offering a potential new treatment option for mCRPC patients, particularly those with del(17p) who face limited therapeutic alternatives. The data underscores Heidelberg Pharma's leadership in Amanitin-based ADC technology, with other candidates like HDP-101 for multiple myeloma and HDP-102 for Non-Hodgkin Lymphoma also advancing in clinical stages, while HDP-103 and HDP-104 for gastrointestinal tumors are available for partnering opportunities.

For more details, the abstract is accessible via the provided link, and additional information about the company can be found on their official website. This news release, distributed through NEWMEDIAWIRE, emphasizes the forward-looking nature of the statements, cautioning investors about potential risks and uncertainties. The presentation at the AACR Annual Meeting 2026 marks a significant milestone in oncology research, potentially paving the way for innovative therapies that could transform cancer treatment paradigms and improve outcomes for patients with hard-to-treat cancers.